BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 21, 2026
Home » Blogs » BioWorld MedTech Perspectives » Device taxes, fiscal cliffs, and the Petraeus-Benghazi imbroglio

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Device taxes, fiscal cliffs, and the Petraeus-Benghazi imbroglio

Nov. 14, 2012
By Mark McCarty

Who needs caffeine at a time like this?

New York may be the town that never sleeps, but Washington is the town that never fails to amaze. We currently have a sex scandal seeming to rival the Bill Clinton-Monica Lewinsky detonation, but the current scandal has more in common with the Profumo affair because a secretary of defense was involved.

Obviously the President has a number of distractions. One of those is Benghazi, a story seeming to grow more convoluted every day. Somewhat linked to all that – more or less immediately – are Gen. David Petraeus, Gen. John Allen, Jill Kelley, and Paula Broadwell (apparently it doesn’t end there, but I just don’t have the stomach for any more).

Then we hear the FBI was investigating the CIA chief purportedly without telling the White House until 5 pm on election day. If that doesn’t stretch your brain, nothing will.

So what does all this have to do with the device tax and the fiscal cliff?

Well, let’s face it: The Benghazi-Petraeus thingamabob and the FBI-watching-the-CIA chief mindblower together constitute a mess that can’t help but distract everyone working within 10,000 feet of the Oval Office (read: Capitol Hill). They’re an enormous pair of problems for anyone who shows up at the White House for work every day, and they will not go away in a week or two.

That leaves the House and Senate for leadership on the Gordian knot known as the fiscal cliff. The GOP still holds the House, but as we discussed previously, Democrats picked up three seats in the Senate, thus giving Senate majority leader Harry Reid more reason to play hardball. And let’s face it. Senator Reid knows from hardball.

If you don’t believe me, remember that Reid alleged earlier this year that Mitt Romney had not paid a dime in federal income taxes for a decade or so, an assertion that proved amazingly dead wrong. Reid never came clean on that utterly unfounded little slur, so why would he suddenly get bashful now?

“We could avoid the fiscal cliff for 98% of Americans today,” Reid is credited with having said recently. Clearly the line has been drawn. Add to that the fact that President Obama has said enough to indicate he believes the election gave him a mandate, and there’s no expectation Democrats will bend much at all, if any, on any hot-button tax matters. One exception would be the R&D tax credit, except that it’s not even remotely controversial.

There are a couple of conclusions to be drawn from all this. One is that the Bush-era tax cuts will lapse for those making more than a quarter of a million bucks a year, and the second is that all the fiscal cliff issues will go down to the wire. Both parties are pretty dug in, and although one cannot rule out the possibility that one side will cave and thus expedite a resolution, it’s rather unlikely. These issues are almost sure to devour enormous amounts of time and energy on the Hill. Hence, it’s tough to see how a device tax repeal is likely to draw much interest in the Senate (let alone draw 60 votes), at least not without offsets.

“Offsets? In this fiscal environment? Are you kidding me? Offsets?” I can almost hear myself saying that in the same tone of voice Jim Mora used in addressing a question about his team making the playoffs a few years back.

I would gently remind the reader that the Medicare physician fee doc fix (a.k.a. SGR) is a $27 billion a year mess Congress has yet to address. Granted the device tax comes to far less than that, but many in Congress might argue they have no business repealing the device tax with SGR hanging over the king’s head.

In other words, good luck with that device tax repeal.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 20, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing